-
1
-
-
61749083299
-
A Flexible Strategy for Testing Subgroups and Overall Population
-
M.Alosh,, and M.F.Huque, (2009), “A Flexible Strategy for Testing Subgroups and Overall Population,” Statistics in Medicine, 28, 3–23.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 3-23
-
-
Alosh, M.1
Huque, M.F.2
-
2
-
-
0035100888
-
Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework
-
Biomarkers Definitions Working Group (2001), “Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework,” Clinical Pharmacology and Therapeutics, 69, 89–95.
-
(2001)
Clinical Pharmacology and Therapeutics
, vol.69
, pp. 89-95
-
-
-
3
-
-
0003804002
-
-
Boca Raton, FL: Chapman Hall/CRC
-
R.J.Carroll,, D.Ruppert,, L.A.Stefanski,, and C.M.Crainiceanu, (2006), Measurement Error in Nonlinear Models: A Modern Perspective (2nd ed.), Boca Raton, FL: Chapman Hall/CRC.
-
(2006)
Measurement Error in Nonlinear Models: A Modern Perspective
-
-
Carroll, R.J.1
Ruppert, D.2
Stefanski, L.A.3
Crainiceanu, C.M.4
-
4
-
-
84949161149
-
Stein's Estimation Rule and Its Competitors – An Empirical Bayes Approach
-
B.Efron,, and C.Morris, (1973), “Stein's Estimation Rule and Its Competitors – An Empirical Bayes Approach,” Journal of the American Statistical Association, 68, 117–130.
-
(1973)
Journal of the American Statistical Association
, vol.68
, pp. 117-130
-
-
Efron, B.1
Morris, C.2
-
9
-
-
84891747501
-
-
Roche Molecular Systems, Inc.
-
——— (2012b), Summary of Safety and Effectiveness Data, Cobas 4800 BRAF V600 Mutation Test, Roche Molecular Systems, Inc. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=P110020
-
(2012)
Cobas 4800 BRAF V600 Mutation Test
-
-
-
10
-
-
84902551498
-
-
Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff
-
——— (2013a), Design Considerations for Pivotal Clinical Inves-tigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf
-
(2013)
Design Considerations for Pivotal Clinical Inves-tigations for Medical Devices: Guidance for Industry
-
-
-
11
-
-
84925514576
-
-
——— (2013b), Labeling Revision, Erbitux (cetuximab), Imclone Inc. available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125084s242lbl.pdf
-
(2013)
Labeling Revision
-
-
-
12
-
-
84925514576
-
-
——— (2013c), Labeling Revision, Ziagen (abacavir sulfate), ViiV Healthcare, available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020977s026,020978s030lbl.pdf
-
(2013)
Labeling Revision
-
-
-
14
-
-
84925514575
-
-
Vectibix (panitumumab), Amgen Inc
-
——— (2014b), Labeling Revision, Vectibix (panitumumab), Amgen Inc. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf
-
(2014)
Labeling Revision
-
-
-
15
-
-
84925514575
-
-
Zelboraf (vemurafenib) Tablet, Hoffmann-La Roche Inc
-
——— (2014c), Labeling Revision, Zelboraf (vemurafenib) Tablet, Hoffmann-La Roche Inc. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202429s006lbl.pdf
-
(2014)
Labeling Revision
-
-
-
18
-
-
0022072706
-
Testing for Qualitative Interaction Between Treatment Effects and Patient Subsets
-
M.Gail,, and R.Simon, (1985), “Testing for Qualitative Interaction Between Treatment Effects and Patient Subsets,” Biometrics, 41, 361–372.
-
(1985)
Biometrics
, vol.41
, pp. 361-372
-
-
Gail, M.1
Simon, R.2
-
19
-
-
52149112915
-
Pharmacogenetics of Hypersensitivity to Abacavir: From PGx Hypothesis to Confirmation to Clinical Utility
-
Mosteller, M., Warren, L. L., Lai, E. H., Brothers, C. H., Cox, C., Nelsen, A. J., Hughes, S., Thorborn, D. E., Stancil, B., Hetherington, S. V., Burns, D. K. and Roses, A. D.
-
A.R.Hughes,, W.R.Spreen,, Mosteller, M., Warren, L. L., Lai, E. H., Brothers, C. H., Cox, C., Nelsen, A. J., Hughes, S., Thorborn, D. E., Stancil, B., Hetherington, S. V., Burns, D. K. and Roses, A. D. (2008), “Pharmacogenetics of Hypersensitivity to Abacavir: From PGx Hypothesis to Confirmation to Clinical Utility,” Pharmacogenomics Journal, 8, 365–374.
-
(2008)
Pharmacogenomics Journal
, vol.8
, pp. 365-374
-
-
Hughes, A.R.1
Spreen, W.R.2
-
21
-
-
0141883593
-
Discussion of “P-Value Adjustments for Sub-Group Analyses,
-
G.G.Koch, (1997), Discussion of “P-Value Adjustments for Sub-Group Analyses,” Journal of Biopharmaceutical Statistics, 7, 323–331.
-
(1997)
Journal of Biopharmaceutical Statistics
, vol.7
, pp. 323-331
-
-
Koch, G.G.1
-
22
-
-
33846447795
-
The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homogenous Across All Subgroups
-
Z.Li,, C.Chuang-Stein,, and C.Hoseyni, (2007), “The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homogenous Across All Subgroups,” Drug Information Journal, 41, 47–56.
-
(2007)
Drug Information Journal
, vol.41
, pp. 47-56
-
-
Li, Z.1
Chuang-Stein, C.2
Hoseyni, C.3
-
23
-
-
0001015815
-
Estimating a Population of Parameter Values using Bayes and Empirical Bayes Methods
-
T.A.Louis, (1984), “Estimating a Population of Parameter Values using Bayes and Empirical Bayes Methods,” Journal of the American Statistical Association, 79, 393–398.
-
(1984)
Journal of the American Statistical Association
, vol.79
, pp. 393-398
-
-
Louis, T.A.1
-
24
-
-
13644270099
-
On the Efficacy of Targeted Clinical Trials
-
A.Maitournam,, and R.Simon, (2005), “On the Efficacy of Targeted Clinical Trials,” Statistics in Medicine, 24, 329–339.
-
(2005)
Statistics in Medicine
, vol.24
, pp. 329-339
-
-
Maitournam, A.1
Simon, R.2
-
25
-
-
38949196447
-
HLA-B*5701 Screening for Hypersensitivity to Abacavir
-
, for the PREDICT-1 Study Team.
-
S.Mallal,, E.Phillips,, G.Carosi,, J.-M.Molina,, C.Workman,, J.Tomažič,, E.Jägel-Guedes,, S.Rugina,, O.Kozyrev,, J.Flores Cid,, P.Hay,, D.Nolan,, S.Hughes,, A.Hughes,, S.Ryan,, N.Fitch,, D.Thorborn,, and A.Benbow,, for the PREDICT-1 Study Team. (2008), “HLA-B*5701 Screening for Hypersensitivity to Abacavir,” New England Journal of Medicine, 358, 568–579.
-
(2008)
New England Journal of Medicine
, vol.358
, pp. 568-579
-
-
Mallal, S.1
Phillips, E.2
Carosi, G.3
Molina, J.-M.4
Workman, C.5
Tomažič, J.6
Jägel-Guedes, E.7
Rugina, S.8
Kozyrev, O.9
Flores Cid, J.10
Hay, P.11
Nolan, D.12
Hughes, S.13
Hughes, A.14
Ryan, S.15
Fitch, N.16
Thorborn, D.17
Benbow, A.18
-
26
-
-
77953682084
-
Regional Differences in Multinational Clinical Trials: Anticipating Chance Variation
-
I.Marschner, (2010), “Regional Differences in Multinational Clinical Trials: Anticipating Chance Variation, Clinical Trials, 7, 147–156.
-
(2010)
Clinical Trials
, vol.7
, pp. 147-156
-
-
Marschner, I.1
-
27
-
-
84155164041
-
Efficacy and Safety of Once Daily Elvitegravir Versus Twice Daily Raltegravir in Treatment-Experienced Patients With HIV-1 Receiving a Ritonavir-Boosted Protease Inhibitor: Randomised, Double-Blind, Phase 3, Non-Inferiority Study
-
Clotet, B., Clumeck, N., Liu, Y. P., Zhong, L., Margot, N., Cheng, A. K., Chuck, S. L., for the Study 145 Team.
-
J.M.Molina,, A.LaMarca,, J.Andrade-Villanueva,, Clotet, B., Clumeck, N., Liu, Y. P., Zhong, L., Margot, N., Cheng, A. K., Chuck, S. L., for the Study 145 Team. (2012), “Efficacy and Safety of Once Daily Elvitegravir Versus Twice Daily Raltegravir in Treatment-Experienced Patients With HIV-1 Receiving a Ritonavir-Boosted Protease Inhibitor: Randomised, Double-Blind, Phase 3, Non-Inferiority Study,” Lancet Infectious Diseases, 12, 27–35.
-
(2012)
Lancet Infectious Diseases
, vol.12
, pp. 27-35
-
-
Molina, J.M.1
LaMarca, A.2
Andrade-Villanueva, J.3
-
28
-
-
84886915956
-
Analytical and Clinical Evaluation of Biomarkers Assays: When are Biomarkers Ready for Prime Time?
-
G.Pennello, (2013), “Analytical and Clinical Evaluation of Biomarkers Assays: When are Biomarkers Ready for Prime Time?” Clinical Trials, 10, 666–676.
-
(2013)
Clinical Trials
, vol.10
, pp. 666-676
-
-
Pennello, G.1
-
29
-
-
36248964740
-
A Note on Stratification in Clinical Trials
-
T.Permutt, (2007), “A Note on Stratification in Clinical Trials,” Drug Information Journal, 41, 719–722.
-
(2007)
Drug Information Journal
, vol.41
, pp. 719-722
-
-
Permutt, T.1
-
30
-
-
0031016256
-
Evaluating Treatment When a Gender by Treatment Interaction May Exist
-
E.Russek-Cohen,, and R.M.Simon, (1997), “Evaluating Treatment When a Gender by Treatment Interaction May Exist,” Statistics in Medicine, 16, 455–464.
-
(1997)
Statistics in Medicine
, vol.16
, pp. 455-464
-
-
Russek-Cohen, E.1
Simon, R.M.2
-
31
-
-
33644910161
-
An Exploration of Aspects of Bayesian Multiple Testing
-
J.G.Scott,, and J.O.Berger, (2006), “An Exploration of Aspects of Bayesian Multiple Testing,” Journal of Statistical Planning and Inference, 136, 2144–2162.
-
(2006)
Journal of Statistical Planning and Inference
, vol.136
, pp. 2144-2162
-
-
Scott, J.G.1
Berger, J.O.2
-
32
-
-
0037108041
-
Bayesian Subset Analysis: Application to Studying Treatment-by-Gender Interactions
-
R.Simon, (2002), “Bayesian Subset Analysis: Application to Studying Treatment-by-Gender Interactions,” Statistics in Medicine, 21, 2909–2916.
-
(2002)
Statistics in Medicine
, vol.21
, pp. 2909-2916
-
-
Simon, R.1
-
33
-
-
34547529442
-
A Method for Testing a Prespecified Subgroup in Clinical Trials
-
Y.Song,, and G.Y.Chi, (2007), “A Method for Testing a Prespecified Subgroup in Clinical Trials,” Statistics in Medicine, 26, 3535–3549.
-
(2007)
Statistics in Medicine
, vol.26
, pp. 3535-3549
-
-
Song, Y.1
Chi, G.Y.2
-
34
-
-
0141918127
-
-
The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. (2002), “Points to Consider on Multiplicity Issues in Clinical Trials London, UK,” available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf
-
(2002)
Points to Consider on Multiplicity Issues in Clinical Trials London, UK
-
-
-
35
-
-
0037287752
-
Testing for Interaction in Studies of Noninferiority
-
B.L.Wiens,, and J.F.Heyse, (2003), “Testing for Interaction in Studies of Noninferiority,” Journal of Biopharmaceutical Statistics, 13, 103–115.
-
(2003)
Journal of Biopharmaceutical Statistics
, vol.13
, pp. 103-115
-
-
Wiens, B.L.1
Heyse, J.F.2
-
36
-
-
79957438038
-
Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
-
Y.D.Zhao,, A.Dmitrienko, and R.Tamura, (2010), “Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation,” Statistics in Biopharmaceutical Research, 2, 72–83.
-
(2010)
Statistics in Biopharmaceutical Research
, vol.2
, pp. 72-83
-
-
Zhao, Y.D.1
Dmitrienko, A.2
Tamura, R.3
|